Follicle-stimulating hormone associates with prediabetes and diabetes in postmenopausal women

Ningjian Wang¹ · Lin Kuang² · Bing Han¹ · Qin Li¹ · Yi Chen¹ · Chunfang Zhu¹ · Yingchao Chen¹ · Fangzhen Xia¹ · Zhen Cang¹ · Chaoxia Zhu¹ · Meng Lu¹ · Ying Meng¹ · Hui Guo¹ · Chi Chen¹ · Dongping Lin¹ · Yingli Lu¹

Abstract

Aims No study explores the association between follicle-stimulating hormone (FSH) and glucose metabolism in general women. We aim to investigate whether the variation of FSH is associated with prediabetes and diabetes in postmenopausal women.

Methods Our data were from survey on prevalence in East China for metabolic diseases and risk factors in 2014. Thousand six hundred and ten postmenopausal women at the age of 55–89 who were not using hormone replacement therapy were selected. Prediabetes and diabetes were defined according to American Diabetes Association 2014 criteria. FSH, luteinizing hormone, total testosterone and estradiol were measured by chemiluminescence. Multinomial logistic analyses were used for the association of FSH with prediabetes and diabetes, and linear regression for the association of FSH with fasting plasma glucose (FPG) and HbA1c.

Results Among the participants, 778 (48.3 %) had prediabetes and 121 (7.5 %) had newly diagnosed diabetes. In linear regression, after full adjustment for demographic variables, metabolic factors, E2 and LH, FSH was associated with FPG and HbA1c ($P < 0.05$). In logistic regression, increased quartiles of FSH were associated with significantly decreased odds ratios of prediabetes and diabetes ($P$ for trend <0.01). This association was attenuated by waist circumference and HOMA-IR, but persisted in fully adjusted model ($P$ for trend <0.05) in which, for the lowest compared with the highest quartile of FSH, the odds ratios of prediabetes and diabetes were 1.93 (95 % CI 1.21–3.08; $P < 0.01$) and 3.02 (95 % CI 1.10–8.31; $P < 0.05$), respectively.

Conclusions Low FSH was associated with prediabetes and diabetes in postmenopausal women. The associations might be partially explained by adiposity and insulin resistance.

Keywords Diabetes · Follicle-stimulating hormone · Postmenopause · Women

Introduction

The principal function of sex steroids acts on the reproduction system, but in the recent decade, their roles in the glucose metabolism have also been revealed. In postmenopausal women, endogenous bioavailable testosterone (T) and estradiol (E2) are positively associated with incident type 2 diabetes mellitus (DM) through adiposity and insulin resistance [1, 2].

Follicle-stimulating hormone (FSH) is known as prerequisites for follicular maturation and regulator of ovarian estrogen synthesis in women. However, the role of FSH in glucose metabolism has not been studied. In female dog, FSH plus luteinizing hormone (LH) treatment increases the serum insulin response to glucose load [3]. Increased LH/FSH ratio is a common characteristic of women with...
polycystic ovary syndrome (PCOS) [4], which is reported to be associated with insulin resistance and obesity in PCOS [5]. A most recent study also found that lower FSH was significantly associated with high prevalence of metabolic syndrome in postmenopausal women, but the sample was relatively small [6]. Though there are no population-based data on the association between FSH and DM in general people, FSH is found to be associated with adiposity in women, which is also a great risk factor for type 2 DM [7–9].

We did a population-based observational investigation named survey on prevalence in East China for metabolic diseases and risk factors (SPECT-China) in 2014 to analyze this association between FSH and type 2 DM in Chinese postmenopausal women older than 55 years. As far as we know, the current analyses are the first one to focus on several possible explanatory factors contributing to the relationship of FSH and type 2 DM, including adiposity, insulin resistance, behavioral and metabolic factors.

Materials and methods

Study population

SPECT-China is a cross-sectional survey on prevalence of metabolic diseases and risk factors in East China (ChiCTR-ECS-14005052, www.chictr.org). A stratified and cluster sampling method was used. The first level of sampling was stratified by rural and urban areas and the second level was by economic development area. From February to June 2014, this study was performed in three sites in urban areas of Shanghai, one site in an urban area of Jiangxi Province, three sites in rural areas in Shanghai, three sites in rural areas in Zhejiang and six sites in rural areas in Jiangxi Province. Adults aged 18 years and older who were Chinese citizens and had lived at their current residence for 6 months or longer were invited to participate in our study. Those with severe communication problems, with acute illness or who were unwilling to participate were excluded. Finally, this study was based on a total number of 1610 postmenopausal women (Fig. 1).

The study protocol was approved by the Ethics Committee of Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent was obtained from all patients for being included in the study.

Biochemical measurements

Venous blood samples were drawn after an overnight fast of at least 8 h. The blood samples for plasma glucose test were collected into vacuum tubes with anticoagulant sodium fluoride and centrifuged on the spot in 1 h after collection. Blood samples were stored at −20 °C when collected and shipped by air in dry ice to a central laboratory within 2–4 h of collection, which was certified by the College of American Pathologists. Glycated hemoglobin (HbA1c) was assessed by high-performance liquid chromatography (MQ-2000PT, China). Plasma glucose and lipid profile including total cholesterol, triglycerides, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) were measured by BECKMAN COULTER AU 680 (Germany). Insulin was detected by chemiluminescence method (Abbott i2000 SR, USA).

Total T, E2, FSH and LH were measured by chemiluminescence (SIEMENS Immulite 2000, Germany). The minimal detectable limit for each hormone was as follows: 0.7 nmol/L (total T), 73.4 pmol/L (E2) and 0.1 IU/L (FSH and LH). The inter-assay coefficients of variation were 6.6 % (total T), 7.5 % (E2), 4.5 % (FSH) and 6.0 % (LH). The intra-assay coefficients of variation were 5.7 % (total T), 6.2 % (E2), 3.8 % (FSH) and 4.9 % (LH).

Clinical and anthropometric measurements

In every site, the same staff group collected all the data. They were trained according to a standard protocol that made them familiar with the specific tools and methods used. Trained staff used a questionnaire to collect information on demographic characteristics, medical history and lifestyle risk factors. Current smoking was defined as having smoked at least 100 cigarettes in one’s lifetime and currently smoking cigarettes [11]. Self-reported educational levels from illiteracy, junior and senior high school, college to postgraduate were recorded. We classified them into illiteracy and non-illiteracy. Body weight, height, waist circumference and blood pressure were measured.
with the use of standard methods as described previously [11]. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Insulin resistance was estimated by the homeostatic model assessment (HOMA-IR) index: [fasting insulin (mIU/L)] × [FPG (mmol/L)]/22.5.

**Definition of variables**

In accordance with American Diabetes Association 2014 criteria, prediabetes was defined as impaired fasting glucose [fasting plasma glucose (FPG) 5.6–6.9 mmol/L] or HbA1c concentrations between 5.7 and 6.4 %, or both, while diabetes was defined as a previous diagnosis by healthcare professionals, FPG 7.0 mmol/L or higher or HbA1c 6.5 % or higher.

In China, the prevalence of diabetes in rural and urban areas is different [11]. Therefore, we took residence area as a covariate. Economic development status also affects diabetes prevalence [11]. Current economic status was assessed by gross domestic product (GDP) per capita of 2013 in each study site. The mean national GDP per capita (6807 US dollars from World Bank) in 2013 was considered as the cutoff point for economic status.

**Statistical analysis**

We performed survey analyses with IBM SPSS Statistics, Version 22 (IBM Corporation, Armonk, NY, USA). All analyses were two-sided. A P value <0.05 was taken to indicate a significant difference. General demographic and laboratory characteristics are summarized as median with interquartile range (IQR) for continuous variables or as number with proportion for categorical variables. To test for differences of characteristics among different glucose tolerance status and FSH quartiles, Kruskal–Wallis test was
used for continuous data with skewed distribution, and Pearson chi-squared test was used for categorical variables. A part of total T (67.7 %) and E2 (66.3 %) was under the minimal detectable limit, and samples with values below the minimal detectable limit were given a value midway between zero and the minimal detectable limit for the analyses: 0.35 nmol/L for total T and 36.7 pmol/L for E2 (10).

The association of FSH (independent variable) with FPG and HbA1c (dependent variables) was assessed by linear regression. Model 1 included terms for age, residence area, economic status and LH. Model 2 included terms for model 1 and E2. Model 3 included terms for model 2, waist circumference and HOMA-IR. Since waist circumference and BMI were highly correlated (Spearman’s correlation coefficient = 0.72; P < 0.01), only waist circumference was used as a measure of adiposity. Model 4 was a fully adjusted model including all covariates in model 3, LDL, HDL, triglycerides, systolic blood pressure and current smoker. Since FPG and HbA1c were non-normally distributed, they were log-transformed. Results were expressed as standardized coefficients. \( R^2 \) represented the coefficient of determination.

FSH and LH were divided into quartiles, with the first quartile representing the lowest one and the fourth quartile the highest. Odds ratio (OR) and 95 % confidence intervals (CI) were calculated using multinomial logistic regression to determine the risk of diabetes and prediabetes for each quartile of FSH and LH, using the highest quartile as the reference. Besides models in linear regression, we also adjusted models for waist circumference and HOMA-IR separately. Interaction effect was tested between FSH and residence area, economic status and waist circumference by adding a multiplicative factor in the logistic regression model.

Sensitivity analyses were performed by additional adjustment for total T, substituting BMI for waist circumference in multivariable models. We also conducted further sensitivity analyses excluding cases whose E2 higher than minimal detectable limit (73.4 pmol/L). Because our menopause was based on age, we performed the regression analyses in women older than 60 years.

**Results**

**Characteristics of the study population**

General demographic and laboratory characteristics of the study population are shown in Table 1. This study recruited 1610 postmenopausal women. Among them, 711 (44.2 %) had normal glucose regulation (NGR), 778 (48.3 %) had prediabetes, and 121 (7.5 %) had newly diagnosed diabetes. Compared with postmenopausal women with NGR, women with diabetes were significantly older and more likely to be residents in rural and high economic development area. These women also had significantly greater BMI, waist circumference, fasting insulin, HOMA-IR, triglycerides and systolic pressure. Compared with the participants with NGR, women with prediabetes and diabetes had comparable levels of total T and E2, but lower levels of FSH [62.4 (31.4) and 54.9 (28.4) vs 69.3 (32.9) IU/L, \( P < 0.01 \)].

Characteristics of postmenopausal women according to serum FSH quartiles are summarized in Table 2. The quartile ranges of FSH in postmenopausal women were ≤50.2, 50.3–64.8, 64.9–82.4 and ≥82.5 IU/L. Compared with women in the highest quartile, women in the lowest quartile had comparable ages, but greater BMI, waist circumference, HbA1c, fasting glucose, fasting insulin, HOMA-IR, triglycerides and systolic pressure. They also had similar total T level, but significantly higher E2.

**Association of FSH with FPG and HbA1c**

Table 3 summarizes the results of the linear regression models studying the association of FSH with FPG and HbA1c. In base model (Table 3, model 1), higher FSH levels were associated with lower log FPG (standardized \( \beta = -0.138 \)) and log HbA1c (standardized \( \beta = -0.138 \); both \( P < 0.001 \)). Further adjustment for E2 did not obviously attenuate the association and change \( R^2 \) (Table 3, model 2). After further adjustment for waist circumference and HOMA-IR, this association largely weakened and \( R^2 \) changed greatly from 0.11 to 0.31 for log FPG and from 0.03 to 0.06 for log HbA1c, but there was still statistical significance (Table 3, model 3). Further adjustment for LDL, HDL, triglycerides and systolic blood pressure and current smoker did not change the association, and there was no change in \( R^2 \) for log FPG (Table 3, model 4).

**Association of FSH with prediabetes and diabetes**

Multinomial logistic regression analyses (Table 4) showed that the risk of prevalent prediabetes and newly diagnosed diabetes decreased across FSH quartiles (\( P \) for trend <0.05 in every model). Compared with women in the highest quartile of FSH (Table 4, model 1), ORs of prediabetes and diabetes in women in the lowest quartile of FSH were 1.96 (95 % CI 1.30, 2.93; \( P < 0.001 \)) and 4.68 (95 % CI 2.02, 10.82; \( P < 0.01 \)), respectively. Adjustment for E2 did not weaken the association of FSH with prediabetes and diabetes (Table 4, model 2).

After further adjustment for waist circumference based on model 2, the \( P \) value changed from <0.001 to 0.002 in prediabetes and from <0.001 to 0.007 in diabetes.
Based on model 2, further adjustment for HOMA-IR changed the \( P \) value from <0.001 to 0.003 in prediabetes and from <0.001 to 0.007 in diabetes (Table 4, model 4). Thus, waist circumference and HOMA-IR comparably attenuated the association between FSH and diabetes. Adjusting for both waist circumference and HOMA-IR weakened the association between FSH and diabetes such further that it was no longer significant in Q3 [OR = 1.62 (95% CI 0.71, 3.69), \( P > 0.05 \)] (Table 4, model 5). Further adjustment for LDL, HDL, triglycerides and systolic blood pressure attenuated this association further in Q2 [OR = 2.43 (95% CI 0.97, 6.13), \( P > 0.05 \)] (Table 4, model 6), but in Q1, there was still statistical significance [OR = 3.02 (95% CI 1.10, 8.31), \( P < 0.05 \)]. It was worth mentioning that LH did not show association with diabetes and prediabetes in every model. No interaction was found between FSH and residence area, economic status and waist circumference.

**Sensitivity analysis**

In sensitivity analysis, using BMI instead of waist circumference in relevant models did not change the observed association (both \( P \) for trend <0.05). Additional adjustment for total testosterone also did not alter the association (both \( P \) for trend <0.05). Furthermore, after exclusion of cases whose E2 was higher 73.4 pmol/L, the association of FSH with prediabetes and diabetes did not significantly change in fully adjusted model (both \( P \) for trend <0.05). Even we raised the cutoff age of menopause to 60 years, the significant association still exists (both \( P \) for trend <0.05).

**Discussion**

In this study, we found that higher FSH level was significantly associated with lower FPG and HbA1c and with lower risk of prevalent prediabetes and diabetes in every model. Further adjustment for waist circumference and HOMA-IR weakened the association between FSH and diabetes such further that it was no longer significant in Q3 [OR = 1.62 (95% CI 0.71, 3.69), \( P > 0.05 \)] (Table 4, model 5). Further adjustment for LDL, HDL, triglycerides and systolic blood pressure attenuated this association further in Q2 [OR = 2.43 (95% CI 0.97, 6.13), \( P > 0.05 \)] (Table 4, model 6), but in Q1, there was still statistical significance [OR = 3.02 (95% CI 1.10, 8.31), \( P < 0.05 \)]. It was worth mentioning that LH did not show association with diabetes and prediabetes in every model. No interaction was found between FSH and residence area, economic status and waist circumference.
postmenopausal women. Adiposity and insulin resistance may partially explain this association. As far as we know, this is the first study to detect the association between FSH level and prediabetes and diabetes in a population-based investigation with a large sample.

Previously, the association of FSH with metabolic disorders was mainly described in premenopausal women with polycystic ovary syndrome (PCOS). Low-normal FSH level, increased serum LH level, and increased LH/FSH ratio have been recognized as common characteristics of women with PCOS [4]. LH/FSH ratio more than 2.5 is believed to be useful to identify women with PCOS [6]. Some reported that it is associated with insulin resistance and obesity in PCOS [5], but another study showed an inconsequential predictive value of the LH/FSH ratio on insulin resistance, which needs further study [12].

In our study, the diabetic patients were older than normal subjects. And in a previous study, it was observed that concentration of FSH declined with aging in women over 70 years [13]. Some may be wondering whether the association between FSH and diabetes was actually because of aging. However, in Table 2, among the FSH quartiles, the age did not significantly decreased or increased ($P = 0.19$). According to correlation analyses, age was not significantly correlated with FSH in our subjects (Spearman’s correlation coefficient $= -0.04$, $P = 0.092$). Meanwhile, in regression models, age was also adjusted. Therefore, we think aging may not affect the association between FSH and diabetes in our study.

We observed that FSH was associated with diabetes partially through its relation to waist circumference and insulin resistance. In Chinese adults, waist circumference may be better than BMI as an alternative measure of body fatness or fat distribution for predicting diabetic and cardiovascular risks [14, 15], and waist circumference and BMI were highly correlated (Spearman’s correlation coefficient $= 0.72$, $P < 0.01$), so we chose waist circumference for adjustment instead of BMI. Previous studies found that FSH was lower in obese participants [7, 16] and that weight loss could even elevate FSH level in overweight

### Table 2 Characteristics of postmenopausal women according to serum follicle-stimulating hormone quartiles

|          | Q1     | Q2  | Q3  | Q4  | $P$  |
|----------|--------|-----|-----|-----|------|
| N        | 406    | 400 | 403 | 401 |      |
| FSH (IU/L) | $\leq$ 50.2 | 50.3–64.8 | 64.9–82.4 | $\geq$ 82.5 |      |
| Age (year) | 63 (9) | 63 (9) | 62 (9) | 62 (9) | 0.19 |
| Metabolic factors |
| BMI (kg/m²) | 25.2 (4.9) | 24.4 (4.6) | 23.8 (4.4) | 23.5 (3.9) | $<0.01$ |
| Waist circumference (cm) | 82.0 (15.0) | 80.0 (12.0) | 78.0 (13.0) | 77.0 (13.0) | $<0.01$ |
| HbA1c (%) | 5.5 (0.6) | 5.4 (0.6) | 5.3 (0.6) | 5.3 (0.6) | $<0.01$ |
| Fasting glucose (mmol/L) | 5.66 (1.00) | 5.56 (0.88) | 5.50 (0.89) | 5.39 (0.81) | $<0.01$ |
| Fasting insulin (pmol/L) | 36.6 (26.9) | 33.9 (23.6) | 33.9 (21.9) | 30.9 (19.1) | $<0.01$ |
| HOMA-IR | 1.32 (1.16) | 1.20 (0.90) | 1.20 (0.82) | 1.10 (0.75) | $<0.01$ |
| LDL-cholesterol (mmol/L) | 3.07 (0.97) | 3.07 (1.03) | 2.98 (0.95) | 3.09 (0.88) | 0.26 |
| HDL-cholesterol (mmol/L) | 1.48 (0.39) | 1.49 (0.44) | 1.52 (0.40) | 1.58 (0.45) | $<0.01$ |
| Triglycerides (mmol/L) | 1.47 (0.97) | 1.43 (1.03) | 1.36 (0.88) | 1.32 (0.79) | $<0.05$ |
| Systolic pressure (mmHg) | 138.0 (29.0) | 136.0 (26.0) | 135.0 (29.0) | 134.0 (28.3) | $<0.05$ |
| Sex-related hormones |
| Total T (nmol/L) | 0.35 (0.48) | 0.35 (0.55) | 0.35 (0.45) | 0.35 (0.45) | 0.27 |
| E2 (pmol/L) | 36.7 (77.3) | 36.7 (56.8) | 36.7 (41.3) | 36.7 (0) | $<0.01$ |
| LH (IU/L) | 15.7 (6.9) | 20.8 (7.4) | 25.3 (8.0) | 34.2 (11.8) | $<0.01$ |
| Demographics |
| Illiteracy (%) | 31.5 | 29.4 | 24.7 | 29.8 | 0.25 |
| Current smoker (%) | 3.8 | 3.0 | 5.4 | 2.7 | 0.23 |
| Residence area {rural/urban (%)} | 76.8/23.2 | 73.3/26.8 | 71.5/28.5 | 71.3/28.7 | 0.25 |
| Economic status {low/high (%)} | 25.4/74.6 | 28.0/72.0 | 23.8/76.2 | 21.4/78.6 | 0.18 |

Data were summarized as median with interquartile range for continuous variables or as number with proportion for categorical variables. Kruskal–Wallis test was used for continuous variables with skewed distribution and Pearson chi-squared test for dichotomous variables.

NGR normal glucose regulation, HOMA-IR homeostasis model assessment-insulin resistance, T testosterone, E2 estradiol, BMI body mass index, FSH follicle-stimulating hormone, LH luteinizing hormone, HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-density lipoprotein

 Springer
relationship between E2 and diabetes [1, 2] and insulin resistance, independent of adiposity [1]. In our study, low FSH was associated with higher FPG and HbA1c [6, 24]. Stefanska et al.’s [24] study indicated that the association between FSH and metabolic syndrome is mainly explained by obesity but not by an association with E2, which is consistent with our results. However, the pathophysiology of the relationship between FSH, adiposity and diabetes is not well determined; in our study, we speculate that FSH may be a protective biomarker of glucose metabolism in postmenopausal women.

The study had some strengths. First, the novelty, it is the first study to detect the association between FSH level and glucose metabolism in a large population-based sample. Second, anthropometric measurements and questionnaires were completed by the same trained research group with strong quality control. Third, our data source is SPECT-China study that was performed in a general population as opposed to a clinic-based population, so the results may be more reflective. However, our study also has some limitations. First, because of cross-sectional study nature, we cannot draw causal relationship between FSH and diabetes. Second, though self-reported age at menopause is the clearest way to classify menopausal status [25], we considered women older than 55 years could be postmenopausal. In China, the overall median age at natural menopause is 50 years, and at the age of 55 years, 97% of women are postmenopausal [26]. Even we raised the cutoff age to 60, the association between FSH and diabetes did not change in fully adjusted model. Thus, we do not expect that this would seriously bias this study. Third, we only measured FSH and E2 for a single time. However, this may not largely affect the results because FSH and E2 are considered to be stable about 2 years after final menstrual period [16]. Finally, we could not collect PCOS data. The first report about PCOS in China we could find was published in 1989 [27], and first Chinese diagnostic criteria were established in 2012. Therefore, when our subjects were at reproductive age, PCOS was not well recognized by physicians and patients two decades ago. Participants may not provide correct information about PCOS. Moreover, the elevation of LH concentration is the main biochemical abnormality of PCOS [28], but our study focused on the FSH.

In conclusion, low FSH was associated with higher FPG and HbA1c and also with higher prevalence of prediabetes and diabetes in postmenopausal women. These associations

### Table 3: Association of FSH with FPG and HbA1c: linear regression

| Dependent variables | Standardized β | P value | $R^2$ |
|---------------------|----------------|---------|-------|
| Log FPG (model 1)   | -0.138         | <0.001  | 0.11  |
| Log FPG (model 2)   | -0.152         | <0.001  | 0.11  |
| Log FPG (model 3)   | -0.092         | 0.007   | 0.31  |
| Log FPG (model 4)   | -0.087         | 0.011   | 0.31  |
| Log HbA1c (model 1) | -0.138         | <0.001  | 0.03  |
| Log HbA1c (model 2) | -0.135         | 0.001   | 0.03  |
| Log HbA1c (model 3) | -0.091         | 0.022   | 0.06  |
| Log HbA1c (model 4) | -0.097         | 0.014   | 0.09  |

$R^2$ represented the coefficient of determination.
might be partially explained by adiposity and insulin resistance. Whether FSH is a protective biomarker of glucose metabolism in postmenopausal women needs further exploration.

Acknowledgments This study was supported by the National Natural Science Foundation of China (Grant numbers 81270885, 81070677); Clinical Potential Subject Construction of Shanghai Jiaotong University School of Medicine (Grant number 2014); the Ministry of Science and Technology in China (Grant number 2012CB524906); the Science and Technology Commission of Shanghai Municipality (Grant number 14495810700); and fund for outstanding academic leaders in Shanghai (Grant number 12XD1403100). The authors thank Weiping Tu, Bin Li and Ling Hu for helping organize this investigation. The authors thank all team members and participants from Shanghai, Zhejiang and Jiangxi Province in the SPECT-China study.

Conflict of interest None.

Table 4 Association of circulating follicle-stimulating hormone and luteinizing hormone with prediabetes and diabetes in postmenopausal women

| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 |
|---------|---------|---------|---------|---------|---------|
| **FSH (IU/L)** | | | | | |
| Q1 (≤50.2) | 1.96 (1.30, 2.93) | 2.12 (1.40, 3.20) | 1.99 (1.29, 3.08) | 1.81 (1.18, 2.79) | 1.79 (1.14, 2.79) |
| Q2 (50.3–64.8) | 1.58 (1.11, 2.25) | 1.64 (1.15, 2.33) | 1.48 (1.03, 2.14) | 1.49 (1.03, 2.14) | 1.40 (0.96, 2.04) |
| Q3 (64.9–82.4) | 1.18 (0.86, 1.62) | 1.20 (0.87, 1.65) | 1.24 (0.89, 1.72) | 1.14 (0.82, 1.58) | 1.19 (0.85, 1.66) |
| Q4 (≥82.5) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| P value for trend | <0.001 | <0.001 | 0.002 | 0.003 | 0.009 |

| **LH (IU/L)** | | | | | |
| Q1 (≤17.9) | 0.81 (0.54, 1.22) | 0.80 (0.53, 1.20) | 0.79 (0.52, 1.21) | 0.82 (0.54, 1.25) | 0.86 (0.55, 1.33) |
| Q2 (18.0–23.6) | 0.91 (0.64, 1.28) | 0.89 (0.63, 1.26) | 0.90 (0.62, 1.29) | 0.88 (0.62, 1.26) | 0.95 (0.65, 1.37) |
| Q3 (23.7–30.7) | 0.84 (0.62, 1.15) | 0.83 (0.61, 1.14) | 0.82 (0.59, 1.13) | 0.83 (0.60, 1.15) | 0.83 (0.59, 1.15) |
| Q4 (≥30.8) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| P value for trend | 0.38 | 0.34 | 0.35 | 0.41 | 0.62 |

| **Diabetes** | | | | | |
| FSH (IU/L) | | | | | |
| Q1 (≤50.2) | 4.68 (2.02, 10.82) | 5.14 (2.19, 12.05) | 3.60 (1.48, 8.75) | 3.59 (1.43, 9.02) | 2.75 (1.06, 7.17) |
| Q2 (50.3–64.8) | 3.64 (1.67, 7.93) | 3.80 (1.74, 8.32) | 2.93 (1.31, 6.53) | 3.03 (1.30, 7.07) | 2.48 (1.05, 5.89) |
| Q3 (64.9–82.4) | 2.78 (1.34, 5.77) | 2.82 (1.36, 5.87) | 2.38 (1.12, 5.04) | 2.15 (0.97, 4.76) | 1.62 (0.71, 3.69) |
| Q4 (≥82.5) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| P value for trend | 0.001 | <0.001 | 0.007 | 0.007 | 0.029 |

| LH (IU/L) | | | | | |
| Q1 (≤17.9) | 1.13 (0.54, 2.37) | 1.11 (0.53, 2.33) | 1.03 (0.47, 2.26) | 1.18 (0.51, 2.69) | 1.15 (0.48, 2.76) |
| Q2 (18.0–23.6) | 0.72 (0.35, 1.45) | 0.70 (0.35, 1.43) | 0.67 (0.32, 1.41) | 0.67 (0.30, 1.47) | 0.73 (0.32, 1.68) |
| Q3 (23.7–30.7) | 0.89 (0.46, 1.71) | 0.88 (0.46, 1.69) | 0.82 (0.41, 1.62) | 0.94 (0.46, 1.94) | 0.86 (0.40, 1.83) |
| Q4 (≥30.8) | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| P value for trend | 0.70 | 0.75 | 0.87 | 0.75 | 0.72 |

Model 1 included terms for age, residence area and economic status
Model 2 included terms for model 1 and E2
Model 3 included terms for model 2, waist circumference
Model 4 included terms for model 2, HOMA-IR
Model 5 included terms for model 2, waist circumference and HOMA-IR
Model 6 was a fully adjusted model including all covariates in model 5, metabolic factors [waist circumference, HOMA-IR, low-density lipoprotein, high-density lipoprotein, triglycerides and systolic blood pressure] and current smoker
No interaction was found between FSH and residence area, economic status and waist circumference
Data were odds ratio (95 % CI). * P < 0.05; † P < 0.01; ‡ P < 0.001
Ethical standard  All human studies have been reviewed and approved by the Ethics Committee of Shanghai Ninth People’s Hospital, Shanghai JiaoTong University School of Medicine.

Human and animal rights  All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent  Informed consent was obtained from all patients for being included in the study.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Golden SH, Dobs AS, Vaidya D, Szkel M, Gapstur S, Kopp P, Liu K, Ouyang P (2007) Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab 92:1289–1299
2. Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A, Gapstur SM, Golden SH (2009) The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab 94:4127–4135
3. Renauld A, Gómez NV, Scaramal JD, Garrido D, Wanke MM (2003) Serum insulin, glucose and non esterified fatty acids after administration of follicle-stimulating and luteinizing hormones in bitches. Medicina (B Aires) 63:28–32
4. Chun S (2014) Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. Clin Exp Reprod Med 41:86–91
5. Banaszewska B, Spaczyński RZ, Pelesz M, Pawelczyk L (2003) Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia. Rocz Akad Med Białymst 48:131–134
6. Stefanska A, Ponikowska I, Cwiklinska-Jurkowska M, Sypniewska G (2014) Association of FSH with metabolic syndrome in postmenopausal women: a comparison with CRP, adiponectin and leptin. Biomark Med 8:921–930
7. Freeman EW, Sammel MD, Lin H, Gracia CR (2010) Obesity and reproductive hormone levels in the transition to menopause. Menopause 17:718–726
8. Kim C, Randolph JF, Golden SH, Labrie F, Kong S, Nan B, Barrett-Connor E (2015) Weight loss decreases follicle stimulating hormone in overweight postmenopausal women. Obesity (Silver Spring) 23:228–233
9. De Pergola G, Maldera S, Tartagni M, Pannacciulli N, Loverro G, Giorgino R (2006) Inhibitory effect of obesity on gonadotropin, estradiol, and inhibin B levels in fertile women. Obesity (Silver Spring) 14:1954–1960
10. Bjørnerem A, Straume B, Midby M, Fossnes B, Sundsfjord J, Svartberg J, Acharya G, Oian P, Berntsen GK (2004) Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromsø Study. J Clin Endocrinol Metab 89:6039–6047
11. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G, 2010 China Noncommunicable Disease Surveillance Group (2013) Prevalence and control of diabetes in Chinese adults. JAMA 310:948–959
12. Dasgupta A, Khan A, Banerjee U, Ghosh M, Pal M, Chowdhury KM, Dasgupta S (2013) Predictors of insulin resistance and metabolic complications in polycystic ovarian syndrome in an eastern Indian population. Indian J Clin Biochem 28:169–176
13. Shaw ND, Srouji SS, Histed SN, McCurnin KE, Hall JE (2009) Aging attenuates the pituitary response to gonadotropin-releasing hormone. J Clin Endocrinol Metab 94:3259–3264
14. Li R, Shi L, Jia J, Li Y, Yang Q, Ruan Y, Chen R, Kan H (2015) Differentiatiing the associations of waist circumference and body mass index with cardiovascular disease risk in a Chinese population. Asia Pac J Public Health 27:NP457–467
15. Zeng Q, He Y, Dong S, Zhao X, Chen Z, Song Z, Chang G, Yang F, Wang Y (2014) Optimal cut-off values of BMI, waist circumference and waist:height ratio for defining obesity in Chinese adults. Br J Nutr 112:1735–1744
16. Randolph JF Jr, Zheng H, Sowers MR, Candall C, Crawford S, Gold EB, Vuga M (2011) Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab 96:746–754
17. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ, Wang DY, Dowsett M, Thomas HV, Hankinson SE, Tioniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturrelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Nerishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C, Endogenous Hormones Breast Cancer Collaborative Group (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:1218–1226
18. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S (2007) Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia 50:2076–2084
19. Mahabir S, Buer DJ, Johnson LL, Hartman TJ, Dorgan JF, Campbell WS, Clevendence BA, Taylor PR (2006) Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:2502–2507
20. Duncan BB, Schmidt MI, Pankow JS, Couper D, Vigo A, Hoogeveen R, Folsom AR, Heiss G, Atherosclerosis Risk in Communities Study (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 52:1799–1805
21. Folsom AR, Golden SH, Boland LL, Szkel M (2005) Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women. Eur J Epidemiol 20:1015–1022
22. Watanabe H, Hayakawa Y (2003) Hypothalamic interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats. Endocrinology 144:4868–4875
23. Dandonna P, Dhindsa S (2011) Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 96:2643–2651
24. Stefanska A, Sypniewska G, Ponikowska I, Cwiklinska-Jurkowska M (2012) Association of follicle-stimulating hormone and sex hormone binding globulin with the metabolic syndrome in postmenopausal women. Clin Biochem 45:703–706
25. WHO Scientific Group (1996) Research on the menopause in the 1990s. World Health Organ Tech Rep Ser 866:1–107
26. Li L, Wu J, Pu D, Zhao Y, Wan C, Sun L, Shen CE, Sun W, Yuan Z, Shen Q, He X, Jiang J, Luo N, He Y, Qian Q, Cai P, Zhang M (2012) Factors associated with the age of natural menopause and menopausal symptoms in Chinese women. Maturitas 73:354–360
27. Yang LC, Zhang XY (1989) Laparoscopy in the diagnosis of polycystic ovarian syndrome. Zhonghua Fu Chan Ke Za Zhi 24:147–149, 189. (Article in Chinese)
28. Franks S (2008) Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 32:1035–1041